Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Molecular Therapeutic Potency of Metformin by Targeting p53-Related Molecules in Mutant p53 Colon Cancer Cell Line

Indonesian Journal of Cancer Chemoprevention · Vol. 7 No. 1 (2016) · hlm. 17–24

DOI
10.14499/indonesianjcanchemoprev7iss1pp17-24
ISSN
2355-8989, 2088-0197
Terbit
2016-02-29
Penerbit
Indonesian Society for Cancer Chemoprevention
Bahasa
eng

Abstrak

Colon cancer is a malignancy in gastrointestinal tract. It causes high mortality rate in global cancer population. However, chemotherapy as its first option therapy is still controversial due to its effectiveness and its adverse effects. Finding supportive and alternative drugs to cure cancer is one of focus in cancer research. A drug which also has anticancer effects is metformin. Metformin is a biguanide antidiabetic which show its potential anticancer benefit in metabolic-related cancers including colon cancer. To investigate anticancer potency of metformin in targeting p53-related molecules. Metformin treatment were divided into 4 groups by 0, 5, 10 and 20 mM concentrations and incubated in 37o C and 5 % CO2 condition for 48 hours. Immunohistochemistry were conducted to asses level of expression of Bax, p21, cyclin D1 and E2F1, respectively. Level of expression were measured by H-SCORE using percentage and intensity calculation. Comparisons of H-SCORE between groups were performed by ANOVA for parametrical data and Kruskal-Wallis for non-parametrical data. Growth inhibition were observed after metformin treatment. Metformin increases Bax expression significantly at all concentrations. p21 expression was also increased after metformin treatment but is not statistically significant. Subsequently, metformin decreases cyclin D1 expression at 10 and 20 mM concentration thus decreased E2F1 expression at 5 and 10 mM concentration. These data suggest that metformin may have potential therapeutic effects in mutant p53 colon cancer cell line by targeting p53-related molecules.Keywords: Colon cancer; p53; Biguanide; Metformin; p53-mutant cell line

Jaringan kolaborasi para penulis

22 penulis · 57 tautan kepenulisan bersama · 9 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Sebelas Maret University
  • IPB University
  • Politeknik Kesehatan Kemenkes Surakarta
  • Universitas Gadjah Mada
  • Umeå University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Budiyanti WiboworiniSebelas Maret University2
Irma Isnafia AriefIPB University1
Anantha SenaSebelas Maret University1
Dono IndartoSebelas Maret University1
Heru SulastomoSebelas Maret University1
Syifa Mahmud Syukran AkbarSebelas Maret University1
Habibie ArifiantoSebelas Maret University1
Niniek PurwaningtyasSebelas Maret University1
Ahmad YasaSebelas Maret University1
Khusnun AlifahSebelas Maret University1
Rosmauli Jerimia FitrianiSebelas Maret University1
laila fitrianiSebelas Maret University1
Eti Poncoini PamungkasariAfiliasi tidak diketahui1
Yodi MahendradhataUniversitas Gadjah Mada1
Yopi Harwinanda ArdesaPoliteknik Kesehatan Kemenkes Surakarta1
Nawi NawiUmeå University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ijcc.chemoprev.org/index.php/ijcc/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Molecular Therapeutic Potency of Metformin by Targeting p53-Related Molecules in Mutant p53 Colon Cancer Cell Line</dc:title>
	<dc:creator>Budiani, Dyah R.</dc:creator>
	<dc:creator>Mahanani, Melani R.</dc:creator>
	<dc:creator>Wibowo, Yohanes C.</dc:creator>
	<dc:creator>Probandari, Ari</dc:creator>
	<dc:creator>Prasetyo, Diding H.</dc:creator>
	<dc:creator>Mudigdo, Ambar</dc:creator>
	<dc:description xml:lang="en-US">Colon cancer is a malignancy in gastrointestinal tract. It causes high mortality rate in global cancer population. However, chemotherapy as its first option therapy is still controversial due to its effectiveness and its adverse effects. Finding supportive and alternative drugs to cure cancer is one of focus in cancer research. A drug which also has anticancer effects is metformin. Metformin is a biguanide antidiabetic which show its potential anticancer benefit in metabolic-related cancers including colon cancer. To investigate anticancer potency of metformin in targeting p53-related molecules. Metformin treatment were divided into 4 groups by 0, 5, 10 and 20 mM concentrations and incubated in 37o C and 5 % CO2 condition for 48 hours. Immunohistochemistry were conducted to asses level of expression of Bax, p21, cyclin D1 and E2F1, respectively. Level of expression were measured by H-SCORE using percentage and intensity calculation. Comparisons of H-SCORE between groups were performed by ANOVA for parametrical data and Kruskal-Wallis for non-parametrical data. Growth inhibition were observed after metformin treatment. Metformin increases Bax expression significantly at all concentrations. p21 expression was also increased after metformin treatment but is not statistically significant. Subsequently, metformin decreases cyclin D1 expression at 10 and 20 mM concentration thus decreased E2F1 expression at 5 and 10 mM concentration. These data suggest that metformin may have potential therapeutic effects in mutant p53 colon cancer cell line by targeting p53-related molecules.Keywords: Colon cancer; p53; Biguanide; Metformin; p53-mutant cell line</dc:description>
	<dc:publisher xml:lang="en-US">Indonesian Society for Cancer Chemoprevention</dc:publisher>
	<dc:contributor xml:lang="en-US"></dc:contributor>
	<dc:date>2016-02-29</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijcc.chemoprev.org/index.php/ijcc/article/view/98</dc:identifier>
	<dc:identifier>10.14499/indonesianjcanchemoprev7iss1pp17-24</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Cancer Chemoprevention; Vol 7, No 1 (2016); 17-24</dc:source>
	<dc:source>2355-8989</dc:source>
	<dc:source>2088-0197</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/view/98/98</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2017 Indonesian Journal of Cancer Chemoprevention</dc:rights>
</oai_dc:dc>